Targeting methyltransferase PRMT5 eliminates leukemia stem cells in chronic myelogenous leukemia

Imatinib-insensitive leukemia stem cells (LSCs) are believed to be responsible for resistance to BCR-ABL tyrosine kinase inhibitors and relapse of chronic myelogenous leukemia (CML). Identifying therapeutic targets to eradicate CML LSCs may be a strategy to cure CML. In the present study, we discove...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Clin Invest
Autors principals: Jin, Yanli, Zhou, Jingfeng, Xu, Fang, Jin, Bei, Cui, Lijing, Wang, Yun, Du, Xin, Li, Juan, Li, Peng, Ren, Ruibao, Pan, Jingxuan
Format: Artigo
Idioma:Inglês
Publicat: American Society for Clinical Investigation 2016
Matèries:
Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5096815/
https://ncbi.nlm.nih.gov/pubmed/27643437
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI85239
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars